250 Events@ 27.5% RRR 208 105 - SoC 145 Events
@ 75% RRR 208 50 - SoC 200 Events...
...IMO those are two very different paradigms, in the 27.5% plan i see a very good difference but IMO QoL of non-MACE patients is then very important (and those are all factors), unlike @75% 208 stands on its own just on MAC...
...IMO +3K patients will be enrolled
...and big kicker is the 18 months on trial on average, i wonder where they got that from as ASSURE etc didn't run that long did they and so i wonder if there will be a specific pacing of enrollment to see if 208 has a "tail" that bring it more into line with SoC...
..that rubish from bareall is just that rubish what was he touting completion by Q3 2016 (for a trial that to date hasn't even started enrolling)